When was RefleXion founded?

RefleXion was founded in 2009 and raised its 1st funding round 1 year after it was founded.

Where is RefleXion located?

RefleXion is headquartered in Hayward, United States. It is registered at Hayward, California.

How many employees does RefleXion have?

As of Jul 31, 2026, the latest employee count at RefleXion is 138.

Is RefleXion a funded company?

RefleXion is a funded company, having raised a total of $542M across 17 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2010.

When was the latest funding round of RefleXion?

RefleXion's latest funding was a $***** Series F round on Nov 13, 2023, with participation from 8 investors.

Where does RefleXion rank among its competitors?

RefleXion ranks 1st amongst 66 active competitors, of which 20 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was EmpNia, which secured $9.1M in Nov, 2025.

Who are the top competitors of RefleXion?

RefleXion's top competitors include Alpha Tau Medical, Mevion Medical Systems and Alpheus Medical. Among them, EmpNia secured the most recent funding round in November, 2025.

RefleXion - 2026 Company Profile, Team, Funding & Competitors

RefleXion is a series F company based in Hayward (United States), founded in 2009 by Akshay Nanduri. It operates as a Provider of biology-guided radiotherapy system. RefleXion has raised $542M in funding from investors like The Rise Fund, Hillenbrand and Ally Bridge Group. The company has 66 active competitors, including 20 funded and 11 that have exited. Its top competitors include companies like Alpha Tau Medical, Mevion Medical Systems and Alpheus Medical.

Company Details

Provider of biology-guided radiotherapy system. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of Lung, prostate, and Breast cancers.

Website: reflexion.com
Social
Phone Number: +1 **********
Registered Address: Hayward, California

Key Metrics

Founded Year

2009

Location

Hayward, United States

Stage

Series F

Total Funding

$542M in 17 rounds

Latest Funding Round

Series F, Nov 13, 2023, $*****

Investors

The Rise Fund & 25 more

Ranked

1^st among 66 active competitors

Employee Count

138 as on Jul 31, 2026

Similar Companies

Alpha Tau Medical & 78 more

View RefleXion's full profile

RefleXion is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
REFLEXION MEDICAL CIN: 264487874 , United States, Active		-	251 (As on Dec 31, 2024)	-

RefleXion has raised a total funding of $542M over 17 rounds. Its first funding round was on Jul 01, 2010. Its latest funding round was a Series F round on Nov 13, 2023 for $*****. 8 investors participated in its latest round. RefleXion has 25 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of RefleXion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2023	5658096	Series F	8945463	6135145	3767594	4450560
Jul 06, 2022	6647561	Conventional Debt	1440771	2219275	8481195	Oxford Finance
Mar 01, 2022	1724270	Series E	6045441	5939497	Ascension & 4 more	The Rise Fund & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of RefleXion's funding rounds and investors

The founders of RefleXion is Akshay Nanduri.

Here are the details of RefleXion's key team members:

Akshay Nanduri: Former Co-Founder of RefleXion and founder of 1 other company.
Contact Info: 3 email addresses

View details of RefleXion's Founder profiles and Board Members

RefleXion's employee count trend

RefleXion has 138 employees as of Jul 26. Here is RefleXion's employee count trend over the years:

Uncover RefleXion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RefleXion include Alpha Tau Medical, Mevion Medical Systems and Alpheus Medical. Here is the list of Top 10 competitors of RefleXion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	RefleXion 2009, Hayward (United States), Series F	Provider of biology-guided radiotherapy system	$542M	T. Rowe Price, Venrock & 24 others	70/100
2nd	Alpha Tau Medical 2015, Tel Aviv (Israel), Public	Developer of radiotherapy technique for the treatment of solid cancer tumors	$55M	Shavit Capital, OurCrowd & 15 others	66/100
3rd	Mevion Medical Systems 2004, Littleton (United States), Series F	Proton therapy systems for oncology	$500M	ProQuest Investments, Yuan Ming Capital & 9 others	60/100
4th	Alpheus Medical 2014, Chanhassen (United States), Series B	Developer of Sonodynamic therapy device for brain cancer	$68M	Samsara BioCapital, Orbimed & 7 others	58/100
5th	ZAP-X 2014, San Carlos (United States), Series E	Developer of gyroscopic radiosurgery platform	$160M	Primavera, Foxconn Electronics & 6 others	57/100
6th	ABK Biomedical 2012, Halifax (Canada), Series D	Developer of imageable embolic medical devices targeting benign and malignant hypervascular tumors	$140M	Varian Medical Systems, F-Prime Capital & 8 others	55/100
7th	Cel-Sci 1983, Vienna (United States), Public	Developer of immunotherapy products for the treatment of cancer and infectious diseases	-	Alpha Capital Partners, Midsummer Capital ... & 7 others	53/100
8th	AiRato 2022, Sendai (Japan), Seed	AI-powered radiation therapy platform for cancer treatment	$4.88M	FFG Venture Business Partners, MTG Ventures ... & 8 others	50/100
9th	Sirtex Medical 1991, Sydney (Australia), Public	Developer of radiation therapy for the treatment of cancer	-	CVC, China Merchants Capital	47/100
10th	EmpNia 2020, Eden Prairie (United States), Series B	Developer of precision imaging and radiation therapy for the treatment of cancer patients	$12.2M	-	46/100